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Abstract. – OBJECTIVE: To evaluate the ex-
pression of microRNA (miR)-551b in patients 
with low and high grade cervical intraepithelial 
neoplasia (CIN) and to find an association with 
high-risk Human Papillomavirus (HR-HPV) infec-
tion-related prognostic biomarkers.
PATIENTS AND METHODS: The expression 
level of miR-551b was determined in 50 paraf-
fin-embedded cervical specimens (10 normal 
squamous epithelium, 18 condylomas, 8 CIN1, 
and 14 CIN2-3) using quantitative Real-time poly-
merase chain reaction (qRT-PCR). χ2-test com-
pared miR-551b expression in different diagnosis 
groups. An Ordered Logistic Regression and a 
Probit correlation were made to correlate miR-
551b expression levels with the cervical tissue 
histological findings. The immunohistochemical 
distribution of p16 and Ki-67 according to histo-
pathological findings was also assessed. 
RESULTS: The distribution of the miR-551b ex-
pression profile was significantly lower in CIN1-3 
samples compared to other histological diagnosis 
groups (condyloma and negative). The expression 
levels were inversely correlated to the cervical 
pathological grade, from negative to CIN2-3. A 1% 
increase in miR-551b expression level produced 
an increase of 19% to the probability of a minor 
histological grade diagnosis in a range from neg-
ative to CIN2-3 and an increase of 13% to the prob-
ability of a negative histological grade diagnosis. 
Among the cases with miR-551b expression < 0.02 
(considered as cut-off value) a significant statisti-
cal correlation was found between p16 and Ki-67 
expression and the diagnosis of CIN2-3.
CONCLUSIONS: Our data showed a signifi-
cant inverse correlation between miR-551b ex-
pression and the histological grading of the le-
sions, suggesting a tumor suppressive function 
in the different stages of cervical dysplasia.
Key Words
MicroRNA, miR-551b, Cervical intraepithelial neo-
plasia, p16, Ki-67.
Introduction
Cervical cancer is one of the very few cancers 
where a precursor stage lasts many years before 
becoming invasive cancer, providing a large op-
portunity for primary and secondary prevention, 
early detection and treatment. Unfortunately, al-
though preventable, there is still a large number 
of women who die of cervical cancer in many 
countries (over 265,000 estimated deaths world-
wide), with a large majority occurring in the less 
developed regions1.
Persistent infection with high-risk Human 
Papillomavirus is the necessary but not the suffi-
cient cause of cervical cancer. While high grade 
cervical intraepithelial neoplasia (CIN2-3) can 
be considered the true precursor of cervical can-
cer, low-grade cervical intraepithelial neoplasia 
(CIN1) and some CIN2 represent the cytopatho-
logical effect of a productive viral infection.
Women can develop CIN at any age; however, 
the age range associated to the higher prevalence 
is between 25 and 35 years2. Most cases of CIN 
remain stable, or undergo a presumably immuno-
logically mediated spontaneous complete regres-
sion without the need of treatment. However, a 
small percentage of cases progresses to invasive 
cervical cancer. Estimates of regression and pro-
gression rates and the proportion of women who 
require treatment are needed. Because there is no 
validated method to predict the likelihood of his-
topathological regression or progression, the stan-
dard of treatment for CIN2-3 is the lesion excision3. 
An increasing number of biomarkers, such as p16, 
HPV genotype persistence, Ki-67, and mRNA are 
found to be important in the management of cer-
vical pathology. The transforming HR-HPV in-
fection of the cervical epithelium is characterized 
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by the increased expression of E6 and E7 genes 
responsible for an uncontrolled cell proliferation, 
immortalization and genomic instability. While E6 
acts through the inhibition of p53 and the raise of 
telomerase activity, E7 inactivates Rb (tumor sup-
pressor protein retinoblastoma) and increases the 
transcription factor E2F inducing cell proliferation. 
Therefore, the enhanced expression of proliferation 
markers, such as Ki-67 and p16, a protein that pro-
motes cell cycle arrest through Rb hyperphosphor-
ylation prevention, is the consequence of Rb inacti-
vation mediated by E7 gene. Among the epigenetic 
changes HR-HPV modifies the host DNA methyla-
tion status and aberrant miRNA expression silenc-
ing of tumor suppressor genes and overexpression 
of oncogenes4.
A class of promising non-invasive biomarkers 
to identify cancer at an early stage is represent-
ed by microRNAs (miRNAs). They are a group 
of short, non-coding, single-stranded RNAs in-
volved in the regulation of gene expression at the 
post-transcriptional level by binding to comple-
mentary sites in the 3’ untranslated region (3’-
UTR) of specific mRNA transcripts, causing their 
degradation or translational repression. They may 
act as oncogenes or tumor suppressor genes de-
pending on the targeted mRNAs, and themselves 
can be regulated by oncogenes or tumor suppres-
sors5,6. Experimental evidence indicates that they 
play a crucial role on cell proliferation, differenti-
ation, apoptosis, organ development and immune 
response in multicellular organism7.
A growing number of dysregulated miRNAs 
has been documented in a variety of human cancer 
including different stages of CIN and cervical can-
cer8-23. Numerous miRNAs are in sites of genomic 
instability closed to the HPV integration hotspots 
and may be influenced by the integrated HPV 
DNA. Thus, characterization of altered miRNAs 
resulting from DNA copy number aberration could 
improve our understanding of tumor initiation and 
progression as well as provide molecular markers 
for early detection, prognosis, and therapy.
The microRNA-551b expression in different can-
cers8-20 is shown in the Table I. This miRNA is locat-
ed in the long arm of chromosome 3 (3q26), a region 
amplified in 77-90% of carcinomas of the cervix21-23. 
While the coding genes in the 3q26.2 amplicon are 
well studied, the potential role of miRNAs located at 
the 3q26 locus remains poorly characterized.
To the best of our knowledge, no studies exist 
about miR-551b and cervical preneoplastic lesions or 
cervical cancer. Thus, we investigated the miR-551b 
expression profile in the histological samples of pa-
tient with normal squamous epithelium, condyloma, 
CIN1, and CIN2-3 to evaluate its clinical hypotheti-
cal role in the management of these lesions.
Patients and Methods
From March to September 2013, 40 patients 
with abnormal cervical cytology and 10 nega-
tives for cervical squamous intraepithelial neo-
plasia or abnormal cytology, were enrolled at the 
Colposcopy and the Low Genital Tract Patholo-
gy Unit at Sant’Andrea Hospital, Sapienza Uni-
versity of Rome. 
We excluded women previously treated for 
cervical or vaginal intraepithelial lesions, those 
that had previously undergone total hysterectomy, 
chemotherapy and/or radiotherapy for gynecolog-
ical or other cancers, and patients with acute gen-
ital infections, immunological disorders or HIV 
positivity.
The cytological exam was reported according 
to the Bethesda System 2011. All patients were 
submitted to colposcopy that was always per-
formed by the same operator (L.A.). Cases with 
abnormal cervical-vaginal cytology had all ade-
quate colposcopy and, in each case, a biopsy was 
obtained from the most significant colposcopy 
pattern. Instead, in cases with negative cytolo-
gy and colposcopy, the colposcopist obtained the 
cervical biopsy sample directly from the uterus 
after a hysterectomy that was performed because 
of benign conditions such as fibromatosis, typical 
endometrial hyperplasia, adenomyosis or uterine 
prolapse. 
Fifty cervical biopsy samples were processed 
and histological diagnoses were classified as fol-
lows: 10 negatives for cervical squamous intraep-
ithelial lesions (normal squamous epithelium), 
18 condylomas, 8 CIN1 and 14 CIN2-3. Micro-
scopic evaluation was performed according to the 
CIN classification (CIN1, CIN2, and CIN3). This 
study was ethically approved by the local Insti-
tutional Review Board and all patients gave their 
informed consent. 
RNA Extraction and qRT-PCR
Total RNA obtained by formalin-fixed paraf-
fin-embedded tissue from 50 patients was isolated 
with High Pure miRNA Isolation Kit, in accor-
dance with manufacturer’s instructions (Roche 
Diagnostics, Indianapolis, IN, USA). RNA con-
centrations were determined with a NanoDrop 
(Thermo Scientific, Waltham, MA, USA).
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All quantitative Real-time polymerase chain 
reaction (qRT-PCR) were performed with Bril-
liant II QRT-PCR, AffinityScript Two-Step 
(Stratagene Products Division, La Jolla, CA, 
USA). Mature hsa-miR-551b was assayed using 
the Taq-Man MicroRNA Assays, in accordance 
with manufacturer’s instructions (Applied Bio-
systems, Foster City, CA, USA). Briefly, RNA 
was reverse transcribed using miRNA-specific 
stem-loop primers (Applied Biosystems, Foster 
City, CA, USA). The mix was incubated at 16°C 
for 15 min, 42°C for 60 min and 75°C for 5 min in 
Applied Biosystems 9600 system. Subsequently, 
Real-time PCR was carried out on a MX3500P 
QPCR System (Agilent Technologies, Santa 
Clara, CA, USA). Samples were normalized to U6 
snRNA (Applied Biosystems). Comparative Re-
al-time PCR was performed in triplicate, includ-
ing no-template controls. Relative expression was 
calculated using the comparative Ct method20.
Table I. MicroRNA-551b expression in different human cancers.
Study Sample Evidence
 
Song, et al8 Epithelial-mesenchymal miR-551b inhibits EMT and metastasis in gastric cancer by
  transition (EMT) and   inhibiting ERBB4. miR-551b and ERBB4 are thus potential
  metastasis of gastric cancer  therapeutic targets for the treatment of gastric cancer.
de Leeuw DC, Acute myeloid leukemia cells  High expression of miR-551b was highly predictive for poor overall
 et al9   survival and correlated with decreased complete remission rate 
   after the first cycle of standard-dose remission induction therapy 
   compared to patients with low expression.
Wei, et al10 Ovarian serous  miR-551b was up-regulated and correlated with the pathological
  cystadenocarcinoma  grade of the malignancy. The inhibition of miR-551b increased the 
   susceptibility to cisplatin and prolonged the survival of the host mice.
Chaluvally- High grade serous ovarian miR-551b was up-regulated and raised STAT3 mRNA levels, 
 Raghavan,  cancer  increasing proliferation of ovarian cancer cells and engendering
 et al11   resistance to chemotherapy.
Lin, et al12 Lung adenocarcinoma  miR-551b expression positively correlated to patient survival as an 
   independent prognostic marker.
Kim, et al13 Terminal respiratory unit  miR-551b was down-regulated in non-TRU as compared
  (TRU) and non-TRU types   to TRU-type adenocarcinoma.
  adenocarcinoma  
Chen, et al14 Gastric cancer miR-551b-3p was significantly downregulated in the gastric cancer 
   tissues, and this downregulation was closely correlated with the 
   degree of differentiation, TNM stage, and lymph-node metastasis.
Chong, et al15 Primary and recurrent serous  miR-551b was over-expressed in recurrent epithelial ovarian cancer
  cystadenocarcinoma  and may be used as biomarkers for prediction of the recurrence of 
   epithelial ovarian cancer.
Haldrup, Serum samples from prostate  A panel of circulating markers including several miRs
 et al16  cancer, benign prostatic  (miR-562/miR-210/miR-501-3p/miR-375/miR-551b) was able to  
  hyperplasia and control patients  identify 84% of patients with prostate cancer
Xu X, et al17 Lung cancer cells with acquired Increased miR-551b expression in cells with acquired apoptosis
  chemoresistance  resistance inhibited the expression of catalase, potentiating reactive 
   oxygen species (ROS) accumulation and the over-expression 
   of the oncoprotein Mucin-1. 
Swierniak,  Papillary thyroid carcinoma and  miR-551b-3p was down-regulated in papillary thyroid carcinoma
 et al18  healthy thyroid specimen   tissue compared with unaffected tissue adjacent to but not 
   infiltrated by tumor from the same patient and non-cancerous 
   thyroid specimen.
Huang, et al19 Papillary thyroid carcinoma 
  and paracancerous normal tissue miR-551b was up-regulated compared to normal tissue.
Dettmer, et al20 Follicular variant of papillary  miR-551b was up-regulated in follicular variant of papillary
  thyroid carcinoma and normal  thyroid carcinoma compared to normal tissue.
  tissue 
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Immunohistochemistry24 
The p16INK4A assessment was performed using 
a set of two different reagents (CINtec® PLUS Kit 
Roche, MTM Laboratories AG, Heidelberg, Ger-
many): a primary monoclonal rabbit antibody clone 
274-11AC3 directed against human Ki-67 protein, 
and a primary monoclonal mouse antibody clone 
E6H4 directed to human p16INK4a protein. A two-
step immunohistochemical assay was performed: 
after microwave antigen retrieval and endogenous 
peroxidase block, a cocktail of the primary anti-
bodies was added for 30 minutes at room tempera-
ture. Visualization reagents comprising a polymer 
reagent conjugated to horseradish peroxidase and 
goat anti-mouse antibody (15 min) and a polymer 
reagent conjugated to alkaline phosphatase and a 
goat anti-rabbit antibody (15 min) were used. The 
samples were then developed with two different 
chromogen reactions based on horseradish perox-
idase-mediated conversion of a DAB chromogen 
(10 min), and alkaline phosphatase-mediated con-
version of Fast Red chromogen (15 min) to visible 
reaction products at the respective antigen sites. A 
squamous cell carcinoma of the cervix with known 
positive staining for p16INK4A was used as the pos-
itive control; an immunoglobulin class-matched 
nonimmune antibody was substituted for the pri-
mary antibody in the negative control. After coun-
terstaining, a two-step mounting protocol was ap-
plied: in a first step an aqueous mounting medium 
and, subsequently, a permanent mounting medium 
were used. The results were evaluated by light mi-
croscopy. The immunohistochemical procedure 
causes two different colored reaction products: a 
red staining of nuclei, which indicates Ki-67 ex-
pression and a brown precipitate (cytoplasm and/or 
nuclei) at the p16INK4a antigen sites. 
Immunohistochemical Scoring
p16 was considered as a positive test result 
when a diffuse staining pattern (continuous stain-
ing of cells of the basal and parabasal cells lay-
ers, with or without staining of cells of superficial 
cells layers) was observed; a focal staining pat-
tern (staining of isolated cells or small cells clus-
ters) or a negative staining pattern was regarded 
as negative. 
Scoring for Ki-67 included nuclear staining 
only, and was scored as 0 (no staining), + (focal 
basal/parabasal staining), ++ (diffuse staining 
confined to the bottom third), +++ (diffuse stain-
ing of the whole epithelium). Our study consid-
ered 0/+ and ++/+++ staining as negative or posi-
tive Ki-67 expression, respectively.
Statistical Analysis
To determine if there is any significant varia-
tion in miR-551b expression profile between his-
tological diagnosis of negative, condyloma, CIN1 
and CIN2-3 we applied the Chi-square test (χ)2 
comparing different diagnosis groups in relation 
to the cut-off of miR expression profile. An Or-
dered Logistic Regression and a Probit correla-
tion were made to identify if miR-551b expression 
profile was correlated to the cervical tissue histo-
logical grade while the age at diagnosis was used 
as control. The p-value < 0.05 was considered as 
statistically significant. Statistical data were ob-
tained using the statistical program STATA 12 SE 
(StataCorp LLC, College Station, TX, USA). 
Results
The mean age of the sample was 35.98 ± 9.5 
years. The correlation between miR-551b expres-
sion and histological diagnosis in cervical sam-
ples showed a rapid increase of the expression at ≥ 
0.02 level of the miR-551b distribution values that 
was considered the cut-off level (Figure 1). 
The difference in the distribution of the miR-
551b expression profile was significantly lower 
(p=0.05) in CIN1-3 samples compared to other 
histological diagnosis groups (condyloma and 
negative). Among the 11 cases with miR-551b 
expression ≥ 0.02, 9 (81.8%) had the histologi-
cal diagnosis of condyloma or normal cervical 
tissue. Conversely, no significant statistical dif-
ference was found in the miR-551b expression 
profile between the following subgroups: CIN2-3 
versus negative+condyloma+CIN1; CIN1 versus 
negative+condyloma+CIN2-3, condyloma ver-
sus negative+CIN1-3; negative versus condylo-
ma+CIN1-3 (Figure 2). Moreover, the analysis of 
the distribution of the miR-551b expression pro-
file within different histological groups through 
an “Ordered Logistic Regression” showed that the 
expression level of miR was inversely correlated 
to the cervical pathological grade, from negative 
to CIN2-3 (Figure 3). A 1% increase in miR-551b 
expression level produced an increase of 19% (p 
= 0.040) to the probability of a minor histologi-
cal grade diagnosis in a range from negative to 
CIN2-3 (Table II). Probit regression analysis indi-
rectly validated this result, showing that a 1% in-
crease in miR-551b expression level produced an 
increase of 13% (p = 0.024) to the probability of a 
negative histological grade diagnosis (Table III). 
No significant correlation was found between the 
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miR-551b expression levels and the patient’s age 
(p = 0.064 and p = 0.282; Tables II and III).
The immunohistochemical distribution of p16 
and Ki-67 according to histopathological find-
ings are summarized in Table IV. Overall, 25 of 
50 cases (50%) were positive for p16 expression, 
assessed by p16/Ki-67 immunoreaction. Posi-
tive dual-staining immunoreactivity was mainly 
found in high-grade lesions (93%) while condy-
loma lesions and CIN1 were positive in 39% and 
25%, respectively. Regarding the proliferation in-
dex, the diagnostic categories with the higher Ki-
67 score were represented by CIN2-3 (71%) and 
CIN1 lesions (62%) while condylomas showed 
decreasing proliferating score (33%). Considering 
the 39 cases with miR-551b expression < 0.02 a 
significant statistical correlation was found be-
tween p16 expression and CIN2-3 (p = 0.001) and 
between Ki-67 expression and CIN2-3 (p = 0.039) 
(Table V). Among the 11 cases with miR-551b 
expression ≥ 0.02 no significant statistical cor-
relation was found between histological diagnosis 
Figure 1. Distribution of the miR-551b 
expression levels. 
Figure 2.Correlation between miR-551b expression profile and histological diagnosis of cervical samples. Y-axis: the expression 
profile of miR-551b is represented in percentage. X-axis: the cut-off <0.02 and ≥0.02 of miR-551b (p=0.05; Pearson χ2=3.8151). 
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and p16 expression. The 2 cases of CIN2-3 with 
miR-551b expression ≥ 0.02 showed no expression 
of Ki-67 and only one was p16 positive.
Discussion
To date, the prognostic value of miRNAs in 
cervical cancer genesis has not been fully inves-
tigated. Recent studies21,25,26 indicate that multiple 
miRNAs have altered expression in Human Papil-
lomavirus (HPV) integrated cervical cancer cells 
compared with HPV-negative cervical cancer 
cells or normal cervical tissues, revealing poten-
tial interactions between dysregulated miRNAs 
and HPV oncoproteins. In addition, altered miR-
NA expression profiles have also been reported 
in CIN and carcinomas as compared with normal 
cervix21,27-36.
We focused on miR-551b because its gene is lo-
cated on the long arm of the chromosome 3 which 
is amplified in several cases of cervical cancer. 
We found that an expression of miR-551b higher 
than 0.02 increased the probability of “negative” 
histological finding. Moreover, our data showed a 
significant inverse correlation between miR-551b 
expression and the histological grading of the le-
sions (condyloma, CIN1, CIN2-3), suggesting a 
tumor suppressive function.
These findings agree with a recent systemat-
Figure 3. Order Logistic Regression: correlation between miR-551b expression profile and histological diagnosis of cervical sam-
ples. Y-axis: the relative expression of miR-551b, X-axis: histologic diagnosis of negative (0), condyloma (1), CIN1 (2), CIN2-3 (3).
  
Table III. Probit correlation between negative and other 
histological diagnoses (condyloma, CIN1, CIN2-3) with 
miR-551b expression levels.
Variable  Coefficient Z p-value
 
miR-551b  0.1327 2.27 0.024
Age 0.0246 1.07 0.282
Constant factor -2.0854 -2.35 0.019
Total cases 50  
Table II. Ordered Logistic Regression between miR-551b 
expression levels and histological diagnosis subgroups 
(negative, condyloma, CIN1, CIN2-3).
Variable  Coefficient Z p-value
 
miR-551b  -0.1988 -2.05 0.040
Age (patient’s age  -0.0503 -1.85 0.064
 at diagnosis date) 
Total cases 50
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ic study of He et al21 showing differentially ex-
pressed miRNAs in consecutive stages of cer-
vical cancer development. The authors reported 
very few changes in miRNA expression in CIN1 
compared to normal tissue, whereas in CIN2 and 
CIN3 more significant changes in miRNA ex-
pression were observed, indicating a “miRNA 
signature” associated with different levels of cel-
lular and nuclear abnormalities.
In some reports21,35,37,38, HPV E7 was reported 
to modulate the expression of miR-15a, miR-15b, 
miR-16, miR-20a-5p, miR-155, miR-203 levels via 
E2F transcription factors. 
Like other investigated miRNAs36-44, we can 
postulate that high-risk HPV infection may af-
fect the miR-551b expression through epigenetic 
changes mediated by oncoproteins E6 and E7. 
These two proteins inactivate p53 and retinoblas-
toma (RB1) protein respectively, leading to un-
controlled cell growth. E7 mediates degradation 
of RB1 protein releasing E2F transcription factor 
which induces transcription of many genes that 
control cellular proliferation.
The role of common single nucleotide polymor-
phisms (SNPs) of E2F transcription factors 1 and 2 
(E2F1 and E2F2) in association with risk of squamous 
cell carcinoma of the head and neck (SCCHN) was 
evaluated. The authors concluded that E2F1 and 
E2F2 genetic variants might jointly play important 
roles in head and neck carcinogenesis44. 
In relation to the p16 expression as a biomark-
er of high-risk HPV infection, p16 positivity in 
condyloma and CIN1 cases was 34.6%. This per-
centage was slightly smaller than both what stated 
in literature from metanalysis of Tsoumpou et al45 
(resulting in 45%) and what included in one of our 
previous study46 which showed a positivity level 
for low-grade lesions of 40.2%. In our work, the 
p16 expression was useful to discriminate low-
grade lesions from CIN2-3, showing a strong sen-
sitivity (93%), but it resulted rather weak in dif-
ferentiating negative cases (30%) from low-grade 
lesions (34.6%). Such conclusion is shared with 
data from the literature, in particular Galgano et 
al47 reported that p16 was useful to distinguish 
high-grade lesions (CIN2-3) vs. ≤ CIN1 but it was 
not useful to discriminate CIN1 from the healthy 
cervix.
The identification of one isolated p16 nega-
tive CIN2-3 case could be explained considering 
the methylation of the p16 promoter resulting in 
silencing the p16 gene48. Promoter hypermethyl-
ation of p16 might be an alternative pathway in 
cervical dysplasia.
The Ki-67 proliferation index expression was 
higher in CIN lesions compared to condylomas 
and negative samples. In literature, this data was 
also confirmed by reports from Kruse et al49, Gal-
gano et al47, and Lim et al50 where Ki-67 expres-
sion at epithelium’s second and third superior was 
significantly higher in CIN2-3 compared to CIN1, 
in which it was isolated to the basal layer (epithe-
lium’s third inferior).
Finally, cases with miR-551b expression with 
cut-off <0.02 showed a significant correlation be-
tween moderate and severe dysplasia and prolif-
eration index Ki-67. Correlation appeared even 
more consistent taking in consideration the p16 
expression. In the literature, there are no studies 
on the involvement of miR-551b in the cervical 
dysplasia process, however, from our results ap-
Table IV. Correlation between p16 and Ki-67 and miR-551b expression according to histological diagnoses.
Histology p16+/tot Ki-67+/tot                                miR-551b 
   <0.02/tot >0.02/tot
 
Negative 3/10 (30%) 4/10 (40%) 6/10 (60%) 4/10 (40%)
Condyloma 7/18 (38.9%) 6/18 (33.3%) 13/18 (72.2%) 5/18 (27.8%)
CIN1 2/8 (25%) 5/8 (62.5%) 8/8 (100%) 0/8 (0%)
CIN2-3 13/14 (92.8%) 10/14 (71.4%) 12/14 (85.7%) 2/14 (14.3%)
Total 25/50 (50%) 25/50 (50%) 39/50 (78%) 11/50 (22%)
Table V. Distribution of p16 and Ki-67 expression between 
different histological subgroups (negative/condyloma/CIN1 
and CIN2-3) with miR-551b expression < 0.02.
 < CIN2-3 (n=27) CIN2-3 (n=12)
 No. (%) No. (%)
 
p16 
– 16 (59.3) 0 (0)
+ 11 (40.7) 12 (100)
Chi2 = 12.06, p = 0.001
Ki-67 
– 14 (51.9) 2 (16.7)
+ 13 (48.1) 10 (83.3)
Chi2 = 4.25, p = 0.039
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pear that a cut-off of 0.02 might discriminate dif-
ferent levels of cervical dysplasia.
Conclusions
We showed that the miR-551b could play an 
important role as oncosuppressor in the different 
stages of cervical dysplasia through the control on 
cell cycle. Despite there have been several find-
ings about the connection between miRs and car-
cinogenesis, it is still necessary to understand all 
target regulated by miRs, in order to increase our 
understanding of cervical dysplasia and carcino-
genesis. Some of the analyzed miRNA could be 
used as biomarkers not only for early diagnosis 
and monitoring of cervical cancer development 
but also for choosing the best therapeutic strategy 
for cervical dysplasia.
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